Prospective randomized human trials, crossover pharmacokinetic studies, and ClinicalTrials.gov interventional readouts with direct participant sample sizes (N). Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Among newly diagnosed patients with T2D, initial TCT effectively lowered HbA1c levels with higher tolerability and safety than SAT for 104 weeks, suggesting a novel strategy for initial combination therapy in T2D patients.
Our findings suggest 24 weeks of empagliflozin treatment was associated with an improvement in blood sugar control, irrespective of the baseline use of metformin therapy.
The combination treatments were as well tolerated as fluoxetine single-drug treatment and more clinically effective.
Slower, flexible titration improved staying on track with medication and reduced side effects without compromising efficacy.
104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the...
Getting both at the same time of ezetimibe with simvastatin, a dual inhibition treatment strategy targeting both cholesterol synthesis and absorption, is well tolerated and provides greater LDL-C-lowering efficacy than...
The GnRH pulse subcutaneous infusion successfully treated male patients with HH, leading to earlier sperm production than that in the HCG/HMG-treated patients.
Of 102 randomized participants, 85 (83.3%) completed follow-up.
Compared with placebo, liraglutide treatment led to a significant downregulation in ceramides, phospholipids and triglycerides, which all are linked to higher risk of CVD.
Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin single-drug treatment, it had no additional effects on insulin sensitivity and vascular inflammatory response.
Enavogliflozin added to metformin significantly improved blood sugar control in patients with T2DM and was non-inferior to dapagliflozin 10 mg, suggesting enavogliflozin as a viable treatment option for patients with...
The combination of escitalopram with BoNT/A is a significantly effective intervention in improving clinical efficacy and reducing the recurrence in patients with GAD and comorbid headache, and we believe that this approach...
Lipid-lowering therapy with simvastatin plus ezetimibe was associated with a better pattern of lipoprotein subfractions than rosuvastatin single-drug treatment.
Of 275 patients screened at 9 heart and blood vessel centers, 199 were enrolled (AML/LOS, n = 101; LOS/HCTZ, n = 98), and 183 completed the study.
It seems that combination therapy by using 5-phosphodiesterase inhibitor and tamsulosin has no significant advantages to improve urinary retention versus tamsulosin alone.
Low-dose ILT may be associated with improved successful pregnancy and live birth rates in RPL patients. These clinical outcomes coincided with changes in purinergic signaling, inflammatory cytokines, and cellular energy status; however, formal mediation cannot be inferred from the present analysis.
When considering both treatment arms, a significant arousal group x time x treatment interaction emerged, highlighting specificity to the sertraline arm.
Cotadutide treatment for 54 weeks improved blood sugar control and weight loss in participants with overweight/obesity and type 2 diabetes.
It is concluded that the Rhodiola capsule shows anti-depressive potency in patients with depression disorder when administered in dosages of either 0.3 or 0.6 g/day over a 12-week period.Rhodiola capsule can improve the...
Sleep disturbance may be one of the clinical signs for severe hypogonadism.
The effect of combined use of atorvastatin and ezetimibe was better than atorvastatin alone, which can effectively reduce the blood lipid levels in diabetic patients with CHD and improve plaque stability.
Clinically insignificant minoxidil blood levels resulted from scalp absorption.
The study was conducted as a gold-standard blind, paired comparison with the preparations being given twice daily.
Corbin Posture Scale scores decreased in both groups (p < 0.05). Pain reduction was greater in the study group (VAS: from 9.00 ± 0.67 to 2.92 ± 1.14 versus from 9.11 ± 0.64 to 7.96 ± 0.75; SF-MPQ: from 27.07 ± 4.41 to 10.07 ± 3.33 versus from 21.33 ± 2.46 to 19.37 ± 2.35; p < 0.001).
In resistance-trained men, 16 weeks of high protein intake did not produce statistically detectable differences in renal biomarker or eGFR changes compared with moderate protein intake, irrespective of training modality.
OnabotA was a cost-effective preventive treatment of chronic migraine versus topiramate. Although OnabotA had higher drug acquisition costs, these were offset by reduced HCRU costs due to fewer migraines, resulting in a low incremental cost per headache-day avoided versus topiramate.
These findings support the integration of gamified OHS training into secondary school curricula to strengthen early safety education in line with the principles of Legislative Decree 81/2008. Future studies should include larger samples, address item-level weaknesses and explore long-term behavioural outcomes.
MBI significantly improved the primary outcome of mindfulness (FFMQ) and showed promising exploratory improvements in processing speed (P300 latency) and sustained attention (CPT-IP). FER change may represent a potential indirect pathway associated with change in SQLS.
We hypothesize that the multimodal program will demonstrate beneficial effects on adolescent psychological outcomes compared with usual practice.
Adding Kunxian capsule to standard therapy with irbesartan improved the proteinuria remission rate and attenuated renal function decline in patients with DKD, supporting its potential as a promising adjunctive therapy.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
